2BBBullish & Bearish
BioCryst Pharmaceuticals, Inc. (BCRX) trades on NASDAQ. It operates in the Health Care sector, Drug Manufacturers - Specialty & Generic industry. Its current 2BB score is 67 out of 100.
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020.
BioCryst Pharmaceuticals, Inc.’s current 2BB score is 67 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 71 | High |
| Momentum | 70 | Improving |
| Financial strength | 75 | Strong |
| Quality | 100 | Very Strong |
| Risk | 45 | Moderate |
| CEO | Jon P. Stonehouse |
| Headquarters | Durham, North Carolina, United States |
| Founded | 1986 |
| Employees | 435 |
| 52-week range | $6.00 – $11.22 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-24 | — | 0.1131 | — | $172.81M |
| 2026-11-02 | — | 0.0836 | — | $168.84M |
| 2026-08-05 | — | 0.1209 | — | $186.16M |
| 2026-05-06 | -0.09 | 0.0495 | $156.41M | $154.15M |